Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Available treatments have either undesirable risk:benefit profiles or severe payer restrictions. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. There is a relatively sparse late-phase pipeline for obesity and a promising volume of activity in early phases of development. However, given the prevalence of obesity, even if effective agents reach the market, stringent payer-controlled usage restrictions are likely to be necessary to limit the impact on healthcare budgets.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.